OBJECTIVE： To evaluate the effectiveness and economics of Oseltamivir phosphate granules combined with Pudilan xiaoyan oral liquid in the treatment of suspected case of children influenza. METHODS： A pragmatic clinical trial （PCT）was conducted. A total of 180 suspected case of children influenza were randomly divided into control group and trial group， with 90 cases in each group. Control group was given Oseltamivir phosphate granules orally. Trial group was additionally given Pudilan xiaoyan oral liquid on the basis of control group. Clinical effects and cost data of children were collected. Cost-effectiveness analysis was conducted from a point of view of the patient. Sensitivity analysis of cost and effectiveness was conducted by multiple linear regression and binary Logistic regression. RESULTS： Totally 80 cases were included in control group， and 82 cases were included in trial group. The response rates of 2 groups were 80.00％ and 95.12％. There were no statistical significance in the incidence of ADR， drug combination except for combination of antibiotics （P＞0.05）； average drug costs were 119.27 and 171.82 yuan， and average total costs were 203.46 and 257.03 yuan. Incremental cost-effectiveness ratio （ICER） of drug was 347.55 and ICER of total cost was 354.30. The results of sensitivity analysis were consistent with that of basic analysis. CONCLUSIONS： Therapeutic efficacy of Oseltamivir phosphate granules combined with Pudilan xiaoyan oral liquid is better than Oseltamivir phosphate granules alone in the treatment of suspected case of children influenza. But Oseltamivir phosphate granules alone are more economical.